Menu Close

Analysis was by modified intention to treat

Analysis was by modified intention to treat. injections of AMG 145 280 mg, 350 mg, or 420 mg, or matching placebo every 4 weeks. Everyone was masked 8-O-Acetyl shanzhiside methyl ester to treatment assignment within the every 2 weeks and every 4 weeks schedules. The primary endpoint was the percentage change in LDL-C concentration from baseline after 12 weeks. Analysis was by altered intention to treat. This study is usually registered with, number “type”:”clinical-trial”,”attrs”:”text”:”NCT01380730″,”term_id”:”NCT01380730″NCT01380730. Findings 631 patients with hypercholesterolaemia were randomly assigned to AMG 145 70 mg (n=79), 105 mg (n=79), or 140 mg (n=78), or matching placebo (n=78) every 2 weeks; or AMG 145 280 mg (n=79), 350 mg (n=79), and 420 mg (n=80), and matching placebo (n=79) every 4 weeks. At the end of the dosing interval at week 12, the mean LDL-C concentrations were reduced generally dose dependently by AMG 145 every 2 weeks (ranging from 41.8% to 66.1%; p 0.0001 for each dose placebo) and AMG 145 every 4 weeks (ranging from 41.8% to 50.3%; p 0.0001). No treatment-related serious adverse events occurred. The frequencies of treatment-related adverse events were comparable in the AMG 145 and placebo groups (39 [8%] of 474 11 Rabbit polyclonal to AGBL5 [7%] of 155); none 8-O-Acetyl shanzhiside methyl ester of these events were severe or life-threatening. Interpretation The results suggest that PCSK9 inhibition could be a new model in lipid management. Inhibition of PCSK9 warrants assessment in phase 3 clinical trials. Funding Amgen. Introduction Reduction in LDL-cholesterol (LDL-C) concentrations has been shown to reduce subsequent cardiovascular events, both in primary and secondary prevention populations;1 the most compelling data were from trials of statins.2 However, many patients do not achieve their goal LDL-C concentration due to an insufficient response, intolerance to the drugs, or both,3 and thus are at risk of subsequent events.4 Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key part in aiding the intracellular degradation of the LDL receptor (LDL-R) within the hepatocyte lyso-some.5 Loss-of-function mutations in PCSK9 increase the number of LDL-Rs available to recycle to the hepatocyte 8-O-Acetyl shanzhiside methyl ester cell surface, resulting in a reduction in LDL-C concentrations and fewer cardiovascular events.6 AMG 145 is a human monoclonal antibody that binds human PCSK9 with high affinity. In phase 1 studies, it reduced LDL-C concentrations up to 64% versus placebo 1 week after a single dose, and up to 81% with repeated weekly doses.7 We therefore tested the hypothesis that, compared with placebo, 12 weeks of AMG 145 would reduce LDL-C concentrations when used in addition to a statin with or without ezetimibe in patients with hypercholesterolaemia. Methods Patients and study design The design and rationale of LAPLACE-TIMI 57 has been described previously.8 Briefly, the study was a multinational, double-blind, placebo-controlled, dose-ranging trial done in 78 centres in five countries (USA, Canada, Denmark, Hungary, and Czech Republic; appendix pp 3C5). Eligible patients (aged 18C80 years) had a history of hypercholesterolaemia and fasting LDL-C concentration greater than 2.2 mmol/L while on a stable dose of statin (with or without ezetimibe) for at least 4 weeks. Patients with severe comorbidities or taking lipid-lowering drugs other than statin or ezetimibe were ineligible. 8-O-Acetyl shanzhiside methyl ester 8 A complete list of inclusion and exclusion criteria is usually provided in the appendix p 6. After signing informed consent, patients entered a screening phase of up to 6 weeks that included 8-O-Acetyl shanzhiside methyl ester fasting laboratory measurements and a one-time sub cutaneous administration of three 2 mL injections of matching placebo to assess their tolerability. The protocol and amendments were approved by the ethics committee at each centre. An independent data monitoring committee met about every 3 months to review trial conduct, data, and adverse events. Data were provided by an independent biostatistical group external to the TIMI Study Group and Amgen (Thousand.